A clinical study testing revumenib, a novel targeted treatment, found 40% of patients with acute leukemia had complete response and showed how the cancer cells resist the drug, investigators at Dana-Farber Cancer Institute and other research centers report in a new pair of studies in the journal Nature.
A research team at Oregon Health & Science University discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common frontline therapies.
